309 related articles for article (PubMed ID: 35167008)
41. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA;
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1239-1246. PubMed ID: 32298807
[TBL] [Abstract][Full Text] [Related]
42. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
43. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
44. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
45. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
46. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
47. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
[TBL] [Abstract][Full Text] [Related]
48. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
[TBL] [Abstract][Full Text] [Related]
49. Differences in lymphoma patients between chimeric antigen receptor T-cell therapy trials and the general population.
Apaydin EA; Richardson AS; Baxi S; Vockley J; Akinniranye O; Larkin J; Motala A; Hempel S
Clin Exp Med; 2022 Feb; 22(1):151-155. PubMed ID: 33997936
[TBL] [Abstract][Full Text] [Related]
50. Chimeric Antigen Receptor T Cells for B-Cell Lymphoma.
Newcomb R; Jacobson C
Cancer J; 2021 Mar-Apr 01; 27(2):107-111. PubMed ID: 33750069
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
52. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
Hunter BD; Chen YB; Jacobson CA
Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
[TBL] [Abstract][Full Text] [Related]
54. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.
Hill L; Lulla P; Heslop HE
Adv Cell Gene Ther; 2019 Jul; 2(3):. PubMed ID: 31777773
[TBL] [Abstract][Full Text] [Related]
55. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
56. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes.
Figura NB; Sim AJ; Jain MD; Chavez JC; Robinson TJ
Expert Rev Hematol; 2022 Dec; 15(12):1023-1030. PubMed ID: 36369950
[TBL] [Abstract][Full Text] [Related]
57. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Fan J; Adams A; Sieg N; Heger JM; Gödel P; Kutsch N; Kaul D; Teichert M; von Tresckow B; Bücklein V; Goesmann G; Li M; Struve N; Trommer M; Linde P; Rosenbrock J; Celik E; Penack O; Stuschke M; Subklewe M; Belka C; von Bergwelt-Baildon M; Borchmann P; Marnitz S; Baues C
Radiother Oncol; 2023 Jun; 183():109580. PubMed ID: 36842663
[TBL] [Abstract][Full Text] [Related]
58. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Perica K; Curran KJ; Brentjens RJ; Giralt SA
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
[TBL] [Abstract][Full Text] [Related]
59. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
60. Practical aspects of CAR-T cell therapy.
Jana M; Tomáš J; Michal K; Kateřina B; Juraj U; Ivo D; Zdeněk K; Roman H
Klin Onkol; 2022; 35(1):44-54. PubMed ID: 35236081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]